October 2019 Diabetes

Given the relatively static rate of seizure freedom with the current antiepileptic drug (AED) armamentarium, a need remains for the development of new compounds to help enable more patients achieve seizure freedom. Fortunately, several investigational therapeutic agents and delivery systems are in phase 3 development, which are being investigated for the treatment of orphan diseases and focal-onset and generalized-onset seizures.

Pet Peeves

By

Coupon clippers, smoke blowers, and other annoyances you encounter.

Generic Product News

By

Febuxostat tablets, pilocarpine hydrochloride tablets, and more

Rx Products

By

A new indication for pembrolizumab, new ophthalmic inserts, and more.

OTC Products

By

Athlete's Foot 2-Way Spray, CBD-infused sunscreen, and more.